Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Elucidating the mechanisms by which elevated MPO leads to poor prognosis and conversely, investigating the beneficial effects of therapeutic MPO inhibition on alleviating disease phenotype, will facilitate future MPO-targeted clinical trials for improving CVD-related outcomes.
|
31847538 |
2020 |
Cardiovascular Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The level of MPO for the CON group was 84 ng/mL (73-87 ng/mL), for the ESRD group 77 ng/mL (11-89 ng/mL) and for the ESRD/CVD group 21 ng/mL (8-47 ng/mL), with a significant statistical difference of the ESRD/CVD group from the CON and ESRD groups (p<0.001).
|
31049900 |
2019 |
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
The most common MPO actions relevant to CVD are generation of dysfunctional lipoproteins with an increased atherogenicity potential, reduced NO availability, endothelial dysfunction, impaired vasoreactivity and atherosclerotic plaque instability.
|
30797769 |
2019 |
Cardiovascular Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Myeloperoxidase activity can contribute to impaired vascular endothelial function and fibrosis in chronic inflammation-related cardiovascular disease.
|
30618054 |
2019 |
Cardiovascular Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
MPO-ANCA+ patients are at higher risk of CVD death than PR3-ANCA+ patients.
|
31846030 |
2019 |
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Myeloperoxidase (MPO) is highly enriched in neutrophils, can inhibit nitric oxide-mediated vasorelaxation in vitro and is associated with increased cardiovascular disease risk.
|
31593502 |
2019 |
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Our study suggests that in addition to mature MPO, circulating pro-MPO may cause oxidative modifications of proteins thereby contributing to cardiovascular disease.
|
29590135 |
2018 |
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Phagocyte-derived myeloperoxidase (MPO) and proinflammatory HDL are associated with metabolic syndrome (MetS) and increased cardiovascular disease risk.
|
30201848 |
2018 |
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Myeloperoxidase (MPO) is a leukocyte-derived redox enzyme that has been linked to oxidative stress and damage in many inflammatory states, including cardiovascular disease.
|
30076263 |
2018 |
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
In conclusion, intracellular monocyte myeloperoxidase was not associated with incident cardiovascular disease in this prospective population-based study.
|
30300402 |
2018 |
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Myeloperoxidase (MPO), a peroxidase enzyme, and alpha-1-acid glycoprotein (AGP), an acute-phase protein, are known to be released in patients with inflammatory conditions and cardiovascular disease (CVD).
|
30181855 |
2018 |
Cardiovascular Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
MPO (myeloperoxidase) is a peroxidase enzyme secreted by activated leukocytes that plays a pathogenic role in cardiovascular disease, mainly by initiating endothelial dysfunction.
|
29507101 |
2018 |
Cardiovascular Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
However, a lack of good animal models for examining the presence and catalytic activity of MPO in vascular lesions has impeded mechanistic studies into CKD-associated cardiovascular diseases.
|
29581235 |
2018 |
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
1.2-(6-(5-Chloro-2-methoxyphenyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl) acetamide (PF-06282999) is a member of the thiouracil class of irreversible inactivators of human myeloperoxidase enzyme and a candidate for the treatment of cardiovascular disease.
|
28685622 |
2018 |
Cardiovascular Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The neutrophil elastase and myeloperoxidase mRNA levels showed significant positive correlation with BMI, serum triglyceride, atherogenic index of plasma and 10-year risk of developing cardiovascular disease.
|
30056589 |
2018 |
Cardiovascular Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
MPO concentrations were significantly associated with higher ADMA levels and an up-regulated circulating RAAS in patients with CVD.
|
28322753 |
2017 |
Cardiovascular Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Additionally, matrix metalloproteinase-8 concentration was associated with the risk for a coronary artery disease event, myocardial infarction and death, and myeloperoxidase concentration with the risk for cardiovascular disease events, stroke and death.
|
28429955 |
2017 |
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Myeloperoxidase (MPO) as enzyme which oxidizes lipoproteins and paraoxonase1 (PON1) as anti-oxidative enzyme have been involved in pathogenesis of cardiovascular disease.
|
30581333 |
2017 |
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
In fully adjusted models, the highest versus lowest quartile of MPO/HDLp was associated with a 74% increase in incident ASCVD (aHR, 1.74, 95% CI 1.12-2.70) and a 91% increase in total incident CVD (aHR, 1.91, 95% CI 1.27-2.85).
|
28645072 |
2017 |
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Together, these data provide new insights into role of MPO and LDL modification in the induction of endothelial dysfunction, which has implications for both the therapeutic use of SCN<sup>-</sup> within the setting of atherosclerosis and for smokers, who have elevated plasma levels of SCN<sup>-</sup>, and are more at risk of developing cardiovascular disease.
|
28818791 |
2017 |
Cardiovascular Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
However, increased MPO levels have been found to be associated with complex and calcified atherosclerotic lesions and incident cardiovascular disease.
|
24746542 |
2014 |
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Recent evidence now suggests that circulating MPO can act as a clinical prognostic indicator for patients with cardiovascular disease.
|
24772664 |
2013 |
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Height, weight, BMI, waist circumference, clinical and metabolic markers, adipokines, and inflammatory (PCR, IL-6, IL-8 and TNF-α) and CVD risk biomarkers (MPO, MMP-9, sE-selectin, sVCAM, sICAM, and PAI-1) were analyzed.
|
23624317 |
2013 |
Cardiovascular Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The nitric oxide synthase inhibitor asymmetrical dimethylarginine (ADMA) and the leukocyte-derived hemoprotein myeloperoxidase (MPO) are associated with cardiovascular diseases.
|
22082678 |
2011 |
Cardiovascular Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
No relationship between neutrophil granulocyte activation and the myeloperoxidase gene - 129 G>A and - 463 G>A promoter polymorphisms: implications for investigations of cardiovascular disease.
|
19877306 |
2009 |